HC Wainwright Issues Pessimistic Outlook for FDMT Earnings

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) – Stock analysts at HC Wainwright decreased their Q3 2025 earnings estimates for shares of 4D Molecular Therapeutics in a research report issued to clients and investors on Tuesday, August 12th. HC Wainwright analyst M. Caufield now anticipates that the company will earn ($1.01) per share for the quarter, down from their previous estimate of ($0.92). The consensus estimate for 4D Molecular Therapeutics’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for 4D Molecular Therapeutics’ Q4 2025 earnings at ($1.05) EPS, FY2025 earnings at ($3.90) EPS, FY2026 earnings at ($4.22) EPS, FY2027 earnings at ($4.82) EPS, FY2028 earnings at ($5.00) EPS and FY2029 earnings at ($3.88) EPS.

FDMT has been the topic of several other research reports. Roth Capital lowered their target price on shares of 4D Molecular Therapeutics from $44.00 to $38.00 and set a “buy” rating on the stock in a report on Tuesday. Barclays dropped their target price on shares of 4D Molecular Therapeutics from $45.00 to $38.00 and set an “overweight” rating on the stock in a report on Friday, May 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Thursday. The Goldman Sachs Group reduced their price objective on shares of 4D Molecular Therapeutics from $51.00 to $44.00 and set a “buy” rating for the company in a research report on Friday, May 9th. Finally, Chardan Capital reissued a “buy” rating and set a $25.00 target price on shares of 4D Molecular Therapeutics in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have given a hold rating and eight have given a buy rating to the stock. According to MarketBeat.com, 4D Molecular Therapeutics has an average rating of “Moderate Buy” and a consensus price target of $30.40.

4D Molecular Therapeutics Stock Performance

Shares of FDMT stock opened at $7.26 on Thursday. 4D Molecular Therapeutics has a 52-week low of $2.23 and a 52-week high of $17.41. The stock has a market cap of $339.04 million, a price-to-earnings ratio of -2.06 and a beta of 2.83. The firm has a fifty day moving average of $4.68 and a 200-day moving average of $4.14.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Monday, August 11th. The company reported ($0.98) EPS for the quarter, missing the consensus estimate of ($0.88) by ($0.10). The company had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.52 million. 4D Molecular Therapeutics had a negative net margin of 594,375.81% and a negative return on equity of 40.15%.

Institutional Trading of 4D Molecular Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in the company. BVF Inc. IL lifted its stake in 4D Molecular Therapeutics by 70.8% in the first quarter. BVF Inc. IL now owns 4,561,289 shares of the company’s stock valued at $14,733,000 after buying an additional 1,890,647 shares during the period. Millennium Management LLC grew its stake in 4D Molecular Therapeutics by 1,607.1% in the 4th quarter. Millennium Management LLC now owns 1,420,723 shares of the company’s stock valued at $7,913,000 after purchasing an additional 1,337,497 shares during the period. Federated Hermes Inc. increased its holdings in 4D Molecular Therapeutics by 33,131.8% in the 1st quarter. Federated Hermes Inc. now owns 1,250,181 shares of the company’s stock worth $4,038,000 after acquiring an additional 1,246,419 shares during the last quarter. JPMorgan Chase & Co. boosted its stake in 4D Molecular Therapeutics by 159.5% in the 4th quarter. JPMorgan Chase & Co. now owns 820,069 shares of the company’s stock worth $4,568,000 after purchasing an additional 504,086 shares during the period. Finally, Cubist Systematic Strategies LLC boosted its stake in 4D Molecular Therapeutics by 2,084.5% in the 4th quarter. Cubist Systematic Strategies LLC now owns 448,831 shares of the company’s stock worth $2,500,000 after purchasing an additional 428,285 shares during the period. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.